ATE548049T1 - Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung - Google Patents
Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossungInfo
- Publication number
- ATE548049T1 ATE548049T1 AT06754207T AT06754207T ATE548049T1 AT E548049 T1 ATE548049 T1 AT E548049T1 AT 06754207 T AT06754207 T AT 06754207T AT 06754207 T AT06754207 T AT 06754207T AT E548049 T1 ATE548049 T1 AT E548049T1
- Authority
- AT
- Austria
- Prior art keywords
- ides
- pyogenes
- proteinase
- autoimmune diseases
- transplant rejection
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 241000193996 Streptococcus pyogenes Species 0.000 title 1
- 206010052779 Transplant rejections Diseases 0.000 title 1
- 235000019833 protease Nutrition 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0511769A GB0511769D0 (en) | 2005-06-09 | 2005-06-09 | Treatment |
| GB0605781A GB0605781D0 (en) | 2006-03-22 | 2006-03-22 | Treatment |
| PCT/EP2006/005454 WO2006131347A2 (en) | 2005-06-09 | 2006-06-08 | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE548049T1 true ATE548049T1 (de) | 2012-03-15 |
Family
ID=36952007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06754207T ATE548049T1 (de) | 2005-06-09 | 2006-06-08 | Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8133483B2 (enExample) |
| EP (1) | EP1901773B1 (enExample) |
| JP (1) | JP5427409B2 (enExample) |
| CN (1) | CN105770871A (enExample) |
| AT (1) | ATE548049T1 (enExample) |
| AU (1) | AU2006256891B2 (enExample) |
| BE (1) | BE2021C505I2 (enExample) |
| CA (1) | CA2611646C (enExample) |
| ES (1) | ES2380950T3 (enExample) |
| FR (1) | FR21C1004I2 (enExample) |
| NL (1) | NL301089I2 (enExample) |
| PL (1) | PL1901773T3 (enExample) |
| PT (1) | PT1901773E (enExample) |
| WO (1) | WO2006131347A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1686302A (en) * | 2000-12-21 | 2002-07-01 | Shire Biochem Inc | Streptococcus pyogenes antigens and corresponding dna fragments |
| US8691544B2 (en) | 2007-05-04 | 2014-04-08 | Glycorex Transplantation Ab | Material for separation of a biomolecule |
| CA2709029A1 (en) | 2007-12-21 | 2009-07-02 | Bianca Eser | Stability testing of antibodies |
| JP5461586B2 (ja) | 2009-02-09 | 2014-04-02 | ロシュ グリクアート アクチェンゲゼルシャフト | 免疫グロブリングリコシル化パターン分析 |
| CA2741965A1 (en) * | 2009-04-22 | 2010-10-28 | Ofir Menashe | Microorganism comprising particles and uses of same |
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| WO2017134274A1 (en) * | 2016-02-04 | 2017-08-10 | Ulrich Von Pawel-Rammingen | New streptococcal proteases |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| KR20220040476A (ko) * | 2019-08-01 | 2022-03-30 | 메모리얼 슬로안 케터링 캔서 센터 | 개선된 면역치료법을 위한 세포 및 이의 용도 |
| JP2022548197A (ja) * | 2019-12-06 | 2022-11-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｖｅｇｆタンパク質組成物及びその製造方法 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| WO2022057942A1 (zh) * | 2020-09-21 | 2022-03-24 | 上海宝济药业有限公司 | 一种药物组合及其应用 |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| JP2024547125A (ja) * | 2021-12-22 | 2024-12-26 | 上海宝済薬業股▲ふん▼有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの変異体の用途 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| US12091694B2 (en) | 2022-11-18 | 2024-09-17 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| EP4646476A1 (en) | 2023-01-06 | 2025-11-12 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| WO2025030053A1 (en) * | 2023-08-01 | 2025-02-06 | Insmed Incorporated | Novel igg proteases and methods of use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003533488A (ja) * | 2000-05-12 | 2003-11-11 | ベス・イスラエル・ディーコニス・メディカル・センター・インコーポレーテッド | 免疫抑制を達成するための組成物および方法 |
| GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
-
2006
- 2006-06-08 PL PL06754207T patent/PL1901773T3/pl unknown
- 2006-06-08 ES ES06754207T patent/ES2380950T3/es active Active
- 2006-06-08 US US11/921,770 patent/US8133483B2/en active Active
- 2006-06-08 AU AU2006256891A patent/AU2006256891B2/en active Active
- 2006-06-08 EP EP06754207A patent/EP1901773B1/en active Active
- 2006-06-08 CN CN201610049256.0A patent/CN105770871A/zh active Pending
- 2006-06-08 JP JP2008515137A patent/JP5427409B2/ja active Active
- 2006-06-08 WO PCT/EP2006/005454 patent/WO2006131347A2/en not_active Ceased
- 2006-06-08 AT AT06754207T patent/ATE548049T1/de active
- 2006-06-08 PT PT06754207T patent/PT1901773E/pt unknown
- 2006-06-08 CA CA2611646A patent/CA2611646C/en active Active
-
2021
- 2021-01-14 NL NL301089C patent/NL301089I2/nl unknown
- 2021-02-04 FR FR21C1004C patent/FR21C1004I2/fr active Active
- 2021-02-09 BE BE2021C505C patent/BE2021C505I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105770871A (zh) | 2016-07-20 |
| EP1901773B1 (en) | 2012-03-07 |
| US8133483B2 (en) | 2012-03-13 |
| AU2006256891A1 (en) | 2006-12-14 |
| JP5427409B2 (ja) | 2014-02-26 |
| NL301089I2 (nl) | 2021-02-04 |
| BE2021C505I2 (enExample) | 2021-05-31 |
| WO2006131347A2 (en) | 2006-12-14 |
| NL301089I1 (enExample) | 2021-01-20 |
| WO2006131347A3 (en) | 2007-05-31 |
| ES2380950T3 (es) | 2012-05-21 |
| AU2006256891B2 (en) | 2011-08-04 |
| CA2611646C (en) | 2015-08-11 |
| EP1901773A2 (en) | 2008-03-26 |
| PT1901773E (pt) | 2012-06-06 |
| FR21C1004I2 (fr) | 2022-01-14 |
| JP2008542418A (ja) | 2008-11-27 |
| FR21C1004I1 (enExample) | 2021-03-26 |
| CA2611646A1 (en) | 2006-12-14 |
| US20100303781A1 (en) | 2010-12-02 |
| PL1901773T3 (pl) | 2012-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE548049T1 (de) | Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung | |
| ATE418346T1 (de) | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| ATE445415T1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| UA104626C2 (ru) | Анти-vegf антитело и его применение | |
| EA200970403A1 (ru) | Бициклические триазолы в качестве модуляторов протеинкиназы | |
| MY160892A (en) | Antibodies to ccr2 | |
| EA201171237A1 (ru) | Антитела к dkk-1 | |
| DE602005021970D1 (de) | Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen | |
| WO2010072740A3 (en) | TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo | |
| CY1113310T1 (el) | Εξανθρωπισμενα αντισωματα ειδικα για nogo-a και φαρμακευτικες χρησεις αυτων | |
| DE502006007982D1 (de) | Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen | |
| ATE542535T1 (de) | Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten | |
| TW200716132A (en) | Novel chemical compounds | |
| ATE494903T1 (de) | Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden | |
| DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
| ATE546154T1 (de) | Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung | |
| DE502004012196D1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen | |
| TW200716579A (en) | Novel chemical compounds | |
| ATE454147T1 (de) | Verwendung von pyrazolopyridinen zur behandlung von kognitiven defiziten | |
| GB0423126D0 (en) | Protein | |
| ATE427754T1 (de) | Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen | |
| DE602004028497D1 (de) | Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen |